Arcus Biosciences ROA 2017-2022 | RCUS

Current and historical return on assets (ROA) values for Arcus Biosciences (RCUS) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Arcus Biosciences ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-12-31 $-0.27B $1.35B -18.54%
2022-09-30 $0.08B $1.39B 5.33%
2022-06-30 $0.07B $1.48B 4.92%
2022-03-31 $0.06B $1.54B 4.76%
2021-12-31 $0.05B $1.59B 4.97%
2021-09-30 $-0.28B $0.84B -32.39%
2021-06-30 $-0.20B $0.90B -23.30%
2021-03-31 $-0.17B $0.94B -22.41%
2020-12-31 $-0.12B $0.77B -21.96%
2020-09-30 $-0.09B $0.81B -21.07%
2020-06-30 $-0.11B $0.48B -41.60%
2020-03-31 $-0.10B $0.18B -45.51%
2019-12-31 $-0.09B $0.20B -37.04%
2019-09-30 $-0.08B $0.22B -32.32%
2019-06-30 $-0.07B $0.24B -26.04%
2019-03-31 $-0.06B $0.26B -19.73%
2018-12-31 $-0.05B $0.28B -17.23%
2018-09-30 $-0.05B $0.29B -18.96%
2018-06-30 $-0.06B $0.29B -31.94%
2018-03-31 $-0.06B $0.31B -47.68%
2017-12-31 $-0.05B $0.19B -111.58%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.194B $0.112B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Biohaven (BHVN) United States $0.913B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.106B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00